Compared with those without BrMs, patients with BrMs had more cases with history of adenocarcinoma (P = 0.0003) and received PD-1/PD-L1 inhibitor-based combination therapy (P = 0.0202). This evidence concerns the gene PDCD1 and adenocarcinoma.